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Abstract: Potentially inappropriate medication (PIM) prescribing in older adults is quite 
  prevalent and is associated with an increased risk for adverse drug events, morbidity, and 
  utilization of health care resources. In the acute care setting, PIM prescribing can be even more 
problematic due to multiple physicians and specialists who may be prescribing for a single patient 
as well as difficulty with medication reconciliation at transitions and limitations imposed by 
hospital formularies. This article highlights critical issues surrounding PIM prescribing in the 
acute care setting such as risk factors, screening tools, and potential strategies to minimize this 
significant public health problem.
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The medication-use process is a complicated progression of steps traditionally 
  consisting of prescribing, communicating orders, dispensing, administering, and 
monitoring.1 At each step, the potential for associated health risks exist; however, 
many preventable problems can occur at the initial prescribing stage.1 While no set 
definition has been established, inappropriate prescribing encompasses the use of 
medications that introduce a significant risk of an adverse drug event (ADE) when 
there exists evidence for an equally or more effective but lower-risk alternative therapy 
for treating the same medical condition.2 Additional situations also include over-use 
of medications at a higher frequency or for longer durations than clinically indicated, 
under-use of medically indicated medications based on ageist or irrational reasons, 
and use of multiple medications that have documented drug–drug interactions or 
  drug–disease interactions.1,2
It is no surprise that inappropriate prescribing commonly occurs in adults aged 
65 years or older, who have a higher prevalence of chronic disease, disability, and depen-
dency than younger adults.3 While only 13% of Americans are aged 65 years or older, 
this group represents the largest per capita consumers of prescription medications.4,5 
A recent survey of 3,500 community-dwelling adults found that over 29% take five or 
more prescription medications, 42% at least one or more over-the-counter medications, 
and 49% at least one or more dietary supplements.4 With increasing life expectancy, 
improved prescription drug coverage through the implementation of the Medicare Part 
D Prescription Drug Benefit Plan, and the emergence of over 50 new drugs per year into 
the United States (US) market, it seems likely that consumption of prescription drugs 
by older adults will continue to increase. Additionally, the continued development of 
life saving and lifestyle-saving medications, as well as direct to consumer marketing, Clinical Interventions in Aging 2010:5 76
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seems to have created an excess dependence on medication 
therapy to solve everyday problems.
A number of studies have documented that potentially 
inappropriate medication (PIM) prescribing in older adults 
is common in the ambulatory setting, nursing homes, and the 
emergency department and that exposure to inappropriate 
medications is associated with increased morbidity, mortality, 
health care resource utilization, and ADEs.5 However, limited 
data exist regarding PIM prescribing in the acute care setting, 
although adults aged 65 years or older account for over 35% 
of annual hospital admissions.6–10 Older adults are also at 
increased risk for hospital readmission. An analysis of fee for 
service Medicare beneficiaries found that 19.6% of patients 
who had been discharged from a hospital were rehospital-
ized within 30 days, and 34.0% were rehospitalized within 
90 days.11 Of note, the hospital environment can be particu-
larly perilous for older adults. Hospitalization has been asso-
ciated with a higher incidence of adverse outcomes including 
functional decline, delirium, and falls as well as ADEs in this 
population.12,13 A meta-analysis of 39 studies found an in-
hospital incidence of ADEs of 6.7% and an incidence of fatal 
ADEs of 0.3%, which may be slightly higher than what has 
been documented in the outpatient setting.14,15 Furthermore, 
older adults in the inpatient setting may be exposed to new 
and possibly unnecessary medications, multiple providers 
and specialists, and restrictive hospital formularies that 
require reconciliation with home medications; all of these 
can increase the risk for PIM prescribing.16,17
In order to address this public health concern in older 
adults, particularly within the hospital environment, it is 
crucial that clinicians have an understanding of potential 
risk factors for PIM prescribing, advantages and limita-
tions of validated drug evaluation tools for identifying PIM 
prescribing, and possible strategic approaches to curtailing 
the problem.
Risk factors for PIM prescribing
No research has yet identified clear risk factors specific to 
PIM prescribing in the hospitalized older adult, but it may 
be possible to extrapolate from an evaluation of the root 
causes for ADEs to develop a potential list. Data in hos-
pitalized patients suggest that advanced age (85 years), 
polypharmacy, and number of comorbidities can contribute 
to an increased likelihood of ADEs.18–21
Advanced age
While complex issues surrounding frailty, social and 
  emotional infrastructure, and economic status can influence 
inappropriate prescribing, the major impact of advanced 
age lies in the context of altered pharmacokinetics (drug 
absorption, distribution, metabolism and excretion), altered 
pharmacodynamics (physiological effects of the drug) and 
age-related changes in body composition and physiology. 
With advanced age, lean body mass and total body water 
decrease, with a relative increase in total body fat. Such 
changes lead to a decreased volume of distribution for 
hydrophilic, narrow therapeutic drugs such as lithium and 
digoxin for which unadjusted dosing can result in higher 
plasma concentrations and possible toxicity. Conversely, 
lipid-soluble drugs such as long-acting benzodiazepines 
have an increased volume of distribution, thereby delaying 
their immediate effects and resulting in potentially dangerous 
accumulation with continued use.22
Advanced age is also associated with a reduction in 
hepatic mass and blood flow. Drugs such as beta-blockers, 
nitrates, and tricyclic antidepressants (TCAs) that exhibit 
significant hepatic first pass metabolism may have a higher 
bioavailability and faster onset, which will warrant initiation 
at lower doses with possible extended administration inter-
vals. Cytochrome P450 oxidation also declines, increasing 
the risk for toxicity and possible drug – drug interactions 
for drugs that are substrates of these enzymes.23 With aging 
also come associated changes in renal structure and sub-
sequent altered drug excretion. Drug dosages eliminated 
via the kidneys should be adjusted for compromised renal 
function. If serum albumin is decreased, the active unbound 
drug concentration will increase for highly protein-bound 
narrow therapeutic drugs such as phenytoin, theophylline, 
warfarin, and digoxin.
Finally, aging is also associated with changes in the end-
organ responsiveness to drugs at receptor or post-receptor 
levels. There is decreased sensitivity to beta-receptors along 
with a possible decreased clinical response to beta-blockers 
and beta-agonists. The central nervous system becomes more 
vulnerable in the elderly to agents that affect brain function 
(eg, opioids, benzodiazepines, and psychotropic drugs).24
Polypharmacy
While treatment of multiple chronic diseases may justify the 
use of several drugs concomitantly, polypharmacy is associ-
ated with an increased risk for ADEs as well as drug-drug and 
drug-disease interactions.25 Goldberg and colleagues found 
that patients taking two drugs face a 13% risk of adverse 
drug–drug interactions, rising to 38% for four drugs and 
to 82% if seven or more drugs are given simultaneously.26 
Duplicate prescribing within the same drug class is prevalent Clinical Interventions in Aging 2010:5 77
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and frequently unrecognized.25,26 ADEs are often treated 
with additional drugs, leading to prescribing cascades.25 
Polypharmacy can also augment the risk for medication non-
adherence, which in turn can lead to suboptimal therapeutic 
effectiveness and poor clinical consequences.27 If providers 
do not recognize the existence of medication nonadherence, 
they may increase the dose of the initial medication or add a 
second agent, increasing not only the cost of therapy but risk 
for an ADE. It is clear that the use of multiple medications 
is associated with an increase in the risk of ADEs. However, 
the use of specific medications, such as atypical and typical 
antipsychotics as well as benzodiazepines should be of par-
ticular concern as well, as these medications are associated 
with decreased patient functioning and increased morbidity 
and mortality.3,28–30
Multiple comorbidities
Among adults aged over 65 years, 84% present with two or 
more chronic conditions, compared with 35% of patients aged 
45 to 65 years.31 Data have shown that having three or more 
comorbities can increase the risk for having a severe ADE by 
2.9–12.6-fold.20 The pervasiveness of comorbidity is espe-
cially apparent in hospitals. In the hospital setting, 60% of 
inpatients had at least one comorbidity, and 37% had two or 
more.32 The leading comorbities were hypertension (29.4%), 
chronic obstructive lung disease (COPD) (12.1%), diabetes 
mellitus (11.8%), fluid/electrolyte disorders (11.7%), iron 
deficiency/anemia (7.9%), and heart failure (5.7%). With 
each comorbidity comes additional exposure to a larger num-
ber of medications as well as new prescribers and special-
ists.32 For example, a Medicare beneficiary with heart failure 
may see on average 15–23 different providers within a given 
year.33 In this scenario, communication between providers, 
flawless transitions of care, and the overall coordination of 
care are crucial, as failure in any of these steps could lead 
to duplication of medications, prescribing of unnecessary 
medications, and drug – drug interactions.
Validated drug utilization  
review tools
Appropriateness of prescribing can be assessed by process 
or outcome measures that are explicit (criterion-based) or 
implicit (judgment-based).5 Explicit indicators are usually 
developed from published reviews, expert opinions, and 
consensus techniques. These measures are usually drug or 
disease oriented and can be applied with little or no clini-
cal judgment. Unfortunately, explicit criteria may not take 
into account all quality indicators of health care as defined 
by national guidelines for an individual patient and their 
preferences, nor do they address the burden of comorbid 
conditions. In implicit approaches, a clinician employs 
patient-specific information and published evidence to form 
judgments about appropriateness. The focus is placed on the 
patient rather than on drugs or diseases. Implicit approaches 
are potentially more sensitive and can account for patients’ 
preferences, but they are time-consuming, depend on the 
users’ knowledge and attitudes, and can have low reliability. 
While no ideal measure exists, the strengths and weaknesses 
of both approaches should be taken into account. Presently, 
four tools exist to evaluate PIM prescribing in older adults.5 
The Beers’ Criteria, Improved Prescribing in the Elderly Tool 
(IPET), and Screening Tool of Older Persons (STOPP) are 
explicit approaches, while the Medication Appropriateness 
Index (MAI) is an implicit model.
The Beers’ criteria
In 1991, Beers and colleagues published the first set of 
explicit criteria for determining PIM use in nursing home 
residents.34 Based on consensus opinion from experts in geri-
atric medicine, long-term care, geriatric and psychogeriatric 
pharmacology and pharmacoepidemiology, they devised a 
list of 30 medications that should be avoided in nursing home 
residents regardless of diagnoses or dose and frequency of 
medication use. This list incorporated certain psychotropic 
medications, antihypertensives, oral hypoglycemic agents, 
nonsteroidal anti-inflammatory drugs (NSAIDs), and analgesic 
agents. In 1997, Beers published a revised and more compre-
hensive set of explicit criteria for potentially inappropriate 
drug use in ambulatory people aged 65 years or older.35 The 
revised criteria were designed to be applicable to all adults aged 
65 years or older regardless of their place of residence (com-
munity or nursing home) or level of frailty. The criteria divided 
potentially inappropriate drugs into three categories: drugs that 
generally should be avoided in older adults; doses, frequencies, 
or durations of specific therapies that vary from those generally 
accepted as appropriate use in elderly persons; and drugs to be 
avoided in combination with a specific co-morbidity. Beers’ 
criteria were again updated in 2003.36 The criteria specify PIMs 
both independent of diagnosis and condition (Table 1) and 
also by specific diagnosis and condition (Table 2). The new 
criteria included additions to the general list of inappropriate 
medications (eg, nitrofurantoin, doxazosin, and amiodarone). 
Fifteen medications and medication classes were removed 
from the 1997 list, eg, the use of beta-blockers (with excep-
tion of propranolol) in those with COPD, asthma, peripheral 
vascular disease and syncope or falls. The co-morbidity list in Clinical Interventions in Aging 2010:5 78
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Table 1 2002 Beers’ criteria for potentially inappropriate medication use with a high severity rating in older adults: Independent 
of diagnosis or condition36
Drug Concern
Amitriptyline, chlordiazepoxide-amitriptyline, perphenazine-amitriptyline Exhibits strong anticholinergic and sedation properties.
Amphetamines and anorexic drugs Use is associated with dependence, hypertension, angina, and myocardial 
infarction;
Amphetamines other than methylphenidate and anorexic drugs can also 
cause CNS side effects.
Amiodarone Associated with QT interval prolongation, may provoke torsades de 
pointes, and lacks efficacy in the elderly.
Antipsychotic medications: mesoridazine, thioridazine Have CNS and extrapyramidal side effects.
Antihistamines and anticholinergic medications: chlorpheniramine, 
  diphenhydramine, hydroxyzine, cyproheptadine, promethazine, 
  tripelennamine, dexchlorpheniramine
Has potent anticholinergic properties and can cause sedation and 
  confusion.
Barbiturates: all barbituratesa except phenobarbital Are highly addictive and cause more adverse effects than most sedative 
or hypnotic drugs.
Benzodiazepines (long-acting): chlordiazepoxide, chlordiazepoxide- 
 amitriptyline, clidinium-chlordiazepoxide, diazepam, quzepam, halazepam, 
chlorazepate
Exhibits long half-life, producing sedation and increasing incidence of falls 
and factures.
Benzodiazepines (short-acting): Lorazepam (doses exceeding 3 mg),  
oxazepam (doses exceeding 60 mg), alprazolam (doses exceeding 2 mg), 
temazpam (doses exceeding 15 mg), triazolam (doses exceeding 
0.125 mg)
Increased sensitivity at higher doses.
Chlorpropramide Has a long half-life leading to possible prolonged hypoglycemia and can 
cause SIADH.
Desiccated thyroid Has cardiac side effects concerns.
Disopyramide Has the most potent negative inotropic properties compared to other 
antiarrhythmic drugs and exhibits significant anticholinergic side effects.
Fluoxetine (daily use) Exhibits a long half-life and risk of producing excessive CNS stimulation, 
sleep disturbances, and agitation.
Flurazepam Exhibits long half-life, producing sedation and increasing incidence of falls 
and factures.
Gastrointestinal antispasmodic drugs: dicyclomine, hyoscyamine,  
propantheline, clidinium-chlordiazepoxide
Have strong anticholinergic side effects and questionable efficacy.
Guanethidine Can cause orthostatic hypotension.
Guanadrel Can cause orthostatic hypotension.
Indomethacin Exhibits greatest CNS side effects compared to other NSAIDs.
Ketorolac Immediate and long-term use should be avoided as older adults have a 
higher incidence of asymptomatic GI pathologic conditions.
Meperidine May cause confusion and may lack effectiveness in doses commonly  
used.
Meprobamate Exhibits highly addictive and sedating properties.
Methyldopa and methyldopa-hydrochlorothiazide May cause bradycardia and exacerbate depression.
Mineral oil Has potential for aspiration side effects.
Muscle relaxants and antispasmodics: methocarbamol, carisoprodol, 
  chlorzoxazone, metaxalone, cyclobenzaprine, oxybutynin  
(not XL formulation)
Are poorly tolerated by elderly patients, exhibit anticholinergic side 
effects, sedation, and weakness; questionable effectiveness at doses 
  tolerated by the elderly.
Nifedipine (short acting only) Causes hypotension and constipation.
Nitrofurantoin Has potential for renal impairment.
NSAIDS (long-term use, longer half-life, non-COX selective): naproxen,  
oxaprozin, piroxicam
Have the potential for produce GI bleeding, renal failure, high blood 
  pressure, and heart failure.
Orphenadrine Causes more sedation and anticholinergic side effects than safer 
  alternatives.
(Continued)Clinical Interventions in Aging 2010:5 79
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Pentazocine Causes more CNS side effects more commonly than other narcotic drugs.
Stimulant laxatives (long-term use only): bisacodyl, cascara sagrada  
and neoloidb
May exacerbate bowel dysfunction.
Ticlopidine No more effective than aspirin and may be considerably more toxic.
Trimethobenzamide  One of the lest effective antiemetic drugs and exhibits extrapyramidal 
side effects.
Abbreviations: COX, cyclooxygenase; CNS, central nervous system; GI, gastrointestinal; NSAIDs, nonsteroidal anti-inflammatory drugs; SIADH, syndrome of inappropriate 
antidiuretic hormone secretion; XL, extended release; except when treating atrial arrhythmias. 
Notes: aExcept when used to control seizures; bExcept in the presence of opiate analgesic use.
Table 2 2002 Beers’ Criteria for potentially inappropriate medication use with a high severity rating in older adults: Considering diagnosis 
and condition. Modified from Reference 36
Disease or condition Drug Concern
Anorexia and malnutrition CNS stimulants: Dextroamphetamine, methylphenidate, 
  methamphetamine, pemolin, and fluoxetine
Concern due to appetite-suppressing effects.
Arrhythmias TCAs (imipramine hydrochloride, doxepin hydrochloride,  
and amitriptyline hydrochloride)
Concern due to proarrhythmic effects and 
ability to produce QT interval changes.
Bladder outflow obstruction Anticholinergics and antihistamines, GI antispasmodics,  
muscle relaxants, oxybutynin, flavoxate, anticholinergics, 
  antidepressants, decongestants, and tolterodine
May decrease urinary flow, leading to urinary 
retention.
Blood clotting disorders or receiving 
anticoagulant therapy
Aspirin, NSAIDs, dipyridamole, ticlopidine, and clopidogrel May prolong clotting time and elevate INR 
values or inhibit platelet aggregation, resulting 
in an increased potential for bleeding.
COPD Long-acting benzodiazepines: chlordiazepoxide, 
  chlordiazepoxide-amitriptyline,clidinium-chlordiazepoxide, 
diazepam, quazepam, halazepam, and chlorazepate;  
β-blockers: propranolol
CNS adverse effects. May induce respiratory 
depression. May exacerbate or cause 
  respiratory depression.
Cognitive impairment Barbiturates, anticholinergics, antispasmodics, and 
muscle Relaxants; CNS stimulants: dextroamphetamine, 
  methylphenidate, methamphetamine, and pemolin
Concern due to CNS-altering effects.
Depression Long-term benzodiazepine use. Sympatholytic agents: 
  methyldopa, reserpine, and guanethidine
May produce or exacerbate depression.
Gastric or duodenal ulcers NSAIDs and aspirin (≥325 mg) (coxibs excluded) May exacerbate existing ulcers or produce 
new/additional ulcers.
Heart failure Disopyramide and high sodium content drugs (sodium and 
sodium salts [alginate bicarbonate, biphosphate, citrate, 
  phosphate, salicylate, and sulfate])
Negative inotropic effect. Potential to 
promote fluid retention and exacerbation  
of heart failure.
Hypertension Phenylpropanolamine hydrochloridea, pseudoephedrine; diet 
pills, and amphetamines
May produce elevation of blood pressure 
secondary to sympathomimetic activity.
Insomnia Decongestants, theophylline, methylphenidate, MAOIs, and 
amphetamines
Concern due to CNS stimulant effects.
Parkinson disease Metoclopramide, conventional antipsychotics, and tacrine Concern due to their antidopaminergic/ 
cholinergic effects.
Seizures or epilepsy Clozapine, chlorpromazine, thioridazine, and thiothixene May lower seizure thresholds.
Stress incontinence α-blockers (doxazosin, prazosin, and terazosin),  
anticholinergics, TCAs (imipramine, doxepin, and  
mitriptyline), and long-acting benzodiazepines
May produce polyuria and worsening of 
incontinence.
Syncope or falls  Short- to intermediate-acting benzodiazepine and TCAs 
  (imipramine, doxepin, and amitriptyline)
May produce ataxia, impaired psychomotor 
function, syncope, and additional falls.
Abbreviations: CNS, central nervous system; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; INR, international normalized ratio; MAOIs, monoamine 
oxidase inhibitors; NSAIDs, nonsteroidal anti-inflammatory drugs; SIADH, syndrome of inappropriate antidiuretic hormone secretion; SSRIs, selective serotonin reuptake 
inhibitors; TCAs, tricyclic antidepressants.
Notes: aRemoved from the market in 2001.Clinical Interventions in Aging 2010:5 80
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turn included new diagnoses such as depression, Parkinson’s 
disease, cognitive impairment, and incontinence.
In the US, the Beers’ criteria have become the most 
popular and accepted explicit tool used for evaluating PIM 
prescribing. In fact, many health plans and pharmacy benefit 
managers have adopted the Beers’ criteria or a modification of 
the list to help identify and target elderly members at risk of 
ADEs associated with PIM prescribing. Beginning in 2006, 
the National Committee for Quality Assurance has included 
a Health Plan Employer Data and Information Set (HEDIS) 
performance measure for the managed care industry to use 
to evaluate the percentage of members aged 65 years or older 
who receive medications that should be avoided. The speci-
fications for this HEDIS performance measure are based on 
the Beers criteria with some modification.37,38
Numerous research studies have employed the Beers’ 
criteria to evaluate PIM prescribing and ADEs in the inpatient 
setting. Using the most updated Beers’ criteria, Gallagher and 
colleagues found that of the 597 admissions admitted to an 
Irish university teaching hospital, inappropriate prescribing 
occurred in 32% of elderly inpatients in which 24%, 6%, 
and 2% were taking one, two, or three inappropriate medi-
cations, respectively.39 Forty-nine percent of patients with 
inappropriate prescriptions were admitted with ADEs from 
the inappropriate medication, and 16% of all admissions were 
associated with such adverse effects. In a US study, Rothberg 
found that of 493,971 hospitalized elderly, 49% received at 
least one inappropriate prescription and 6% received three 
or more. The most common inappropriate medications 
prescribed consisted of promethazine, diphenhydramine, 
and propoxyphene.8 However, controversy exists regard-
ing exposure to PIMs and ADEs. In a study of 389 elderly 
inpatients, Page and Ruscin demonstrated that while 27.5% 
of inpatients received a drug listed on the Beers’ criteria and 
32% did experience an ADE, only 9.2% of ADEs were attrib-
uted to a Beers’ criteria medication.40 In fact, after controlling 
for covariates, prescription of a Beers’ criteria medication 
was not significantly associated with experiencing an ADE, 
discharge to higher levels of care, or in-hospital mortality.
The use of a list of medications, such as the Beers’ 
criteria, as a sole measurement for PIM prescribing has 
disadvantages. First, the inclusion of some drugs is subject 
to controversy, and insufficient evidence exists to support 
inclusion of some drugs presently on the Beers’ medica-
tion list. Second, the prescription of drugs that should be 
avoided is a relatively minor problem when compared with 
other categories of inappropriate prescribing such as under- 
and over-use of medications, drug–drug interactions, drug 
disease interactions, or drug duplication. The Beers’ criteria 
do not address any of these facets. Third, the reliability of 
the process to generate such lists is not established. Fourth, 
while the Beers’ criteria may be easy to use, they lack com-
prehensiveness, organization, and structure.
Improved prescribing in the elderly  
tool (IPET)
Referred to as the “Canadian Criteria”, the IPET consists 
of a list of the 14 most prevalent prescription errors identi-
fied from a long list of inappropriate prescription instances 
drawn up by an expert Canadian Consensus Panel in 1997 
(Table 3).41 The IPET was initially validated in a prospective 
study of acutely hospitalized elderly patients that demon-
strated PIM prescribing in 12.5% of patients.41 However, 
little use of this instrument exists outside of Canada with the 
exception of one Irish study that found that 22% of acutely 
hospitalized elderly were taking at least one inappropriate 
prescription medication at the point of admission.42 Further-
more, as with the Beers’ criteria, insufficient convincing 
evidence exists regarding IPET’s efficacy to reduce ADR 
incidence, reduce excessive health resource utilization or 
decrease mortality. The IPET only cites 14 instances of inap-
propriate prescribing, three of which relate solely to TCAs, 
which are infrequently used in today’s medical practice. 
Table 3 The improving prescribing in the elderly tool (IPET). 
  Modified with permission from Naugler and colleagues41
The following medications represent potentially inappropriate 
prescriptions in an elderly patient:
β-blocker and chronic obstructive airways disease
β-blocker and congestive heart failure
Calcium channel blocker (excluding amlodipine and feldopine) and 
congestive heart failure
Thiazide diuretic and gout
Long half-life benzodiazepines (chlordiazepoxide, chlorazepate, diazepam, 
flurazepam, clonazepam, nitrazepam)
Tricyclic antidepressant and glaucoma
Tricyclic antidepressant and heart block
Tricyclic antidepressant with active metabolites (imipramine, doxepin, or 
amitriptyline)
Methylphenidate for depression
Nonsteroidal anti-inflammatory drugsa and peptic ulcer disease
Nonsteroidal anti-inflammatory drugs and hypertension
Long term use of nonsteroidal anti-inflammatory drugs for osteoarthritis
Anticholinergic drugs to treat side effects of antipsychotic medications
Long term diphenoxylate to treat diarrhea
Notes: aConsider acetylsalicylic acid as a nonsteroidal anti-inflammatory drug only 
if the dose is greater than 1300 mg/day.Clinical Interventions in Aging 2010:5 81
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Furthermore, the IPET is outdated as it recommends against 
the use of beta-blockers in heart failure contrary to current 
guidelines and published evidence. Finally, IPET is heavily 
weighted towards cardiovascular drug use, psychotropic drug 
use, and NSAID use and is not organized in any particular 
order or structure.
Screening tool of older persons (STOPP)
Developed by a multidisciplinary team of Irish geriatricians, 
pharmacists, pharmacologists, and primary care physicians, 
the STOPP incorporates commonly encountered instances of 
PIM prescribing in older adults that include drug–drug and 
drug–disease interactions, drugs that adversely affect older 
patients at risk of falls, and duplicate drug class prescriptions 
(Table 4).43 Its criteria are arranged according to relevant 
physiological systems for ease of use, and each criterion is 
accompanied by a concise explanation as to why the prescrip-
tion is potentially inappropriate.43
The performance of the STOPP and Beers criteria has 
been evaluated for detecting PIM prescribing and related 
ADRs in 715 older patients admitted a university teaching 
hospital in Ireland.44 The STOPP identified 336 PIMs affect-
ing 35% of patients, one-third of whom presented with an 
associated ADE, while the Beers’ criteria identified 226 PIMs 
affecting 25% of patients, of whom 43% presented with an 
associated ADE. The STOPP-related PIMs contributed to 
11.5% of all admissions, while the Beers’ criteria-related 
PIMs contributed to significantly fewer admissions (6%). 
The most common PIMs identified by STOPP included 
use of long-acting benzodiazepines, TCAs with clear-cut 
Table 4 STOPP: screening tool of older persons’ potentially inappropriate prescriptionsa,43,44
System Drug or drug class Conditions and concerns (in italics)
Cardiovascular Aspirin •    In combination with warfarin without a histamine type 2 receptor 
antagonist (except cimetidine due to warfarin interaction) or PPI 
due to high risk of GI bleeding.
•   With a past history of PUD without a histamine 2 receptor antago-
nist due to risk of bleeding.
•    In doses exceeding 150 mg/day due to increased bleeding risk and 
lack of evidence for increased efficacy.
•   With no history of coronary, cerebral, or peripheral vascular symp-
toms or occlusive event as aspirin is not indicated.
•   To treat dizziness not clearly attributable to cerebrovascular disease 
as aspirin is not indicated.
•   With concurrent bleeding disorder due to high risk of bleeding.
β-blockers •   With COPD due to risk of increased bronchospasm.
•    In combination with verapamil due to increased risk of symptomatic 
heart block.
Calcium channel blockers •    Use of verapamil or diltiazem in patients with NYHA class III or IV 
heart failure due to increased risk of toxicity.
•   With chronic constipation as this may exacerbated constipation.
Clopidogrel •   With concurrent bleeding disorder due to high risk of bleeding.
Digoxin •    For long term use in doses 125 mcg/day with impaired renal func-
tion (GFR  50 ml/min) due to increased risk of toxicity.
Dipyridamole •   As monotherapy for cardiovascular secondary prevention due to 
lack of evidence.
•   With concurrent bleeding disorder due to high risk of bleeding.
Loop diuretics •    For dependent ankle edema only (ie, no clinical signs of heart 
failure) due to lack of evidence and compression hosiery usually more 
appropriate.
Thiazide diuretics •   With a history of gout as this may exacerbate gout.
Warfarin •    In combination with aspirin without a histamine type 2 receptor 
antagonist (except cimetidine due to warfarin interaction) or PPI 
due to high risk of GI bleeding.
•    For 1st uncomplicated pulmonary embolism for longer than 
12 months duration due to lack of proven benefit.
•   With concurrent bleeding disorder due to high risk of bleeding.
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Table 4 (Continued)
System Drug or drug class Conditions and concerns (in italics)
CNS Anticholinergics •   To treat extra-pyramidal side effects of neuroleptic medications due 
to risk of anticholinergic toxicity.
Antihistamines (first generation): 
diphenydramine, chlorpheniramine, 
cyclizine, promethazine
•    Prolonged use (1 week) due to risk of sedation and anticholinergic 
side effects.
Benzodiazepines (long-acting): 
chlordiazepoxide, fluazepam, nitrazepam, 
chlorazepate
•   Avoid due to high risk of prolonged sedation, confusion, impaired 
  balance, and falls.
Benzodiazepines (with long metabolites):  
dizaepam
•   Avoid due to high risk of prolonged sedation, confusion, impaired 
  balance, and falls.
Neuroleptics •   With long term use of 1 month due to high risk of confusion, hypo-
tension, extra-pyramidal side effects, and falls.
•   With long term use of 1 month in patients with Parkinson’s 
disease due to risk worsening, extra-pyramidal symptoms.
Phenothiazines •  In patients with epilepsy as phenothiazines may lower seizure threshold.
SSRIs •   With a history of clinically significant hyponatremia defined as noni-
atrogenic sodium 130 meq/L within the previous two months.
TCAs •   With dementia due to risk of worsening cognitive impairment.
•   With glaucoma as TCAs may exacerbate glaucoma.
•   With cardiac conduction abnormalities due to TCAs’ pro-arrhythmic 
effects.
•   With constipation as TCAs may worsen constipation.
•   With opiate or calcium channel blockers as TCAs may worsen 
constipation.
•   With prostatism or prior history of urinary retention due to 
increased risk of urinary retention.
GI Anticholinergic antispasmodic drugs •   With chronic constipation due to risk of constipation exacerbation.
Diphenoxylate, loperamide, or codeine 
phosphate
•    For treatment of diarrhea of unknown cause due to risk of delayed 
diagnosis, possible exacerbation of constipation with overflow diarrhea, 
precipitation of toxic megacolon in inflammatory bowel disease, and 
delayed recovery in unrecognized gastroenteritis.
•    For treatment of severe infective gastroenteritis (ie, bloody diar-
rhea, high fever or severe systemic toxicity) due to risk of exacerba-
tion or protraction of infection.
Prochlorperazine, metoclopramide •   With Parkinsonism due to risk of exacerbating Parkinsonism.
PPIs •    For PUD at full therapeutic dosage for 8 weeks.
Respiratory Corticosteroids (systemic) •    For maintenance therapy in moderate to severe COPD instead of 
inhaled corticosteroids due to unnecessary exposure to long-term side 
effects of systemic steroids.
Ipratropium (nebulized) •    In patients with glaucoma due to possible glaucoma exacerbation.
Theophylline •   As monotherapy for COPD as more safer, more effective alternatives 
exist and the risk of adverse effects due to narrow therapeutic index.
Musculoskeletal NSAIDs •   With a history of PUD or GI bleeding, unless with concurrent 
histamine type 2 receptor blocker, PPI or misoprostol due to risk of 
PUD relapse.
•   With moderate (160/100–179/109 mmHg) or severe 
(180/110 mmHg) hypertension due to risk of exacerbation of 
hypertension.
•   With heart failure due to risk of heart failure exacerbation.
•   With warfarin concomitantly due to risk of GI bleeding.
•   With chronic renal failure (GFR 20–50 ml/min) due to risk of dete-
rioration in renal function.
•   With long-term use (3 months) for relief of mild joint pain in 
osteoarthritis as simple analgesics preferable and usually as effective 
for pain relief.
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Table 4 (Continued)
System Drug or drug class Conditions and concerns (in italics)
Colchicine •    For chronic treatment of gout where there is no contraindication 
to allopurinol as allopurinol is considered first choice for prophylaxis in 
gout.
Corticosteroids •    For chronic treatment of gout where there is no contraindication 
to allopurinol as allopurinol is considered first choice for prophylaxis in 
gout.
•   As long-term (3 months) monotherapy for rheumatoid arthritis 
or osteoarthritis due to risk of major systemic corticosteroid  
side-effects.
Urogenital Antimuscarinic drugs •   With dementia due to risk of increased confusion and agitation.
•   With chronic glaucoma due to risk of acute exacerbation of glaucoma.
•   With chronic constipation due to risk of exacerbation of constipation.
•   With chronic prostatism due to risk of urinary retention.
α-blockers •    In males with frequent incontinence (ie, one or more episodes of 
incontinence daily) due to risk of urinary frequency and worsening 
incontinence.
•   With long term urinary catheter in situ (ie, more than two months) 
as drug is not indicated.
Endocrine Chlorpropamide or glibenclamide •   With type 2 diabetes due to risk of prolonged hypoglycemia.
β-blockers •    In those with diabetes mellitus and frequent hypoglycemic episodes 
(ie, 1 episodes/month) due to risk of masking hypoglycemic symp-
toms.
Estrogen •   With a history of breast cancer or VTE due to increased risk of 
recurrence.
•   Without progestogen in patients with intact uterus due to risk of 
endometrial cancer.
Drug issues
Analgesic drugs Opiates •    Use of long-term power opiates (eg, morphine or fentanyl) as first 
line therapy for mild-moderate pain as WHO analgesic ladder is not 
observed.
•    Regular use for more than two weeks in those with chronic consti-
pation without use of laxitatives due to risk of severe constipation.
•    Long-term use in those with dementia unless indicated for palliative 
care or management of moderate-severe chronic pain syndrome 
due to risk of exacerbation of cognitive impairment.
Duplicate drug class ACE inhibitors •    Use of any two concurrent duplicate medications as optimization 
of monotherapy within a single drug class should be observed prior to 





Drugs adversely affecting 
those prone to fallsb
Antihistamines (first generation) •    May cause sedation and impair sensorium.
Benzodiazepines •    May cause sedation and impair sensorium.
Neuroleptic drugs •    May cause gait dyspraxia and Parkinsonism.
Opiates •    Long-term use in those with recurrent falls due to risk of drowsiness, 
postural hypotension, and vertigo.
Vasodilators (known to cause hypotension) •    In those with persistent postural hypotension  
(ie, recurrent 20 mmHg drop in systolic blood pressure) due to 
risk of syncope and falls.
Abbreviations: ACE, angiotensin-converting enzyme; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; NYHA, New York 
Heart Association; NSAIDs, nonsteroidal anti-inflammatory drugs; PPIs, proton pump inhibitors; PUD, peptic ulcer disease; SSRIs, selective serotonin re-uptake inhibitors; TCAs, 
tricyclic antidepressants; VTE, venous thromboembolism; WHO, World Health Organization.
Notes: aThe following prescription drugs are potentially inappropriate in persons ages 65 years of age; b1 fall in the past three months.Clinical Interventions in Aging 2010:5 84
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  contraindications, first generation antihistamines, vasodilator 
drugs known to cause hypotension in patients with persistent 
postural hypotension, inappropriate use of NSAIDs and 
opiates, and duplicate drug class prescriptions such as two 
angiotensin converting enzyme inhibitors, two NSAIDs, two 
selective serotonin reuptake inhibitors or dual antiplatelet 
therapy without indication. The authors concluded that 
compared to the Beers’ criteria the STOPP criteria are more 
sensitive in identifying patients liable to suffer harm from 
an ADE because of PIM prescribing.
The advantages of the STOPP consist of good inter-
rater reliability, inclusion of both American and European 
medications, organization and structure based physiological 
systems, and short time to complete (∼3 minutes). However, 
this European tool needs to be evaluated in additional studies 
and in other settings.
Medication appropriateness index (MAI)
Initially developed by Dr Joseph Hanlon and colleagues, 
the MAI is a validated measure of prescribing appropriate-
ness that assesses ten elements of prescribing: indication, 
effectiveness, dose, correct directions, practical directions, 
drug–drug interactions, drug–disease interactions, dupli-
cation, duration, and cost.45 While this implicit approach 
requires clinical judgment to assess criteria, the index has 
operational definitions and explicit instructions, which stan-
dardize the rating process. The ratings generate a weighted 
score that serves as a summary measure of prescribing appro-
priateness ranging from 0 to 18 (0 = no item inappropriate; 
18 = all items inappropriate). Three components of the MAI 
(indication, effectiveness, and duplication) can be used to 
detect unnecessary polypharmacy and PIM prescribing.17,46
In an evaluation of 11 Veterans Affairs Medical Centers 
involving 397 frail elderly inpatients, Hanlon and colleagues 
found that 92% of subjects had at least one drug with one 
or more inappropriate ratings. The most common problems 
involved expensive drugs (70%), impractical directions 
(55.2%), and incorrect dosages (50.9%).6 The most prevalent 
medication classes with appropriateness concerns consisted of 
gastric (50.6%), cardiovascular (47.6%), and central nervous 
system (23.9%) agents. In a similar inpatient population, 
Hajjar and colleagues found that 44% of frail elderly inpatients 
had at least one unnecessary medication at discharge.17 From 
their analysis, the factors most commonly associated with 
unnecessary drug prescribing consisted of hypertension diag-
nosis, multiple prescribers, and nine or more medications.
The MAI as a tool to evaluate PIM prescribing has 
major advantages: it has been tested in both the inpatient 
and ambulatory settings, exhibits excellent intra-rater and 
inter-rater reliability, and has face and content validity. It 
addresses multiple components of prescribing appropriate-
ness, and can be applied to every medication in the context 
of patient-specific characteristics. However, the tool is more 
time-consuming to complete (∼10 minutes per drug assessed) 
and does not assess under-prescribing (untreated indica-
tions).46 Most studies using the MAI have been performed 
in a single setting, with groups of elderly veterans from the 
Veterans Affairs Medical Center in Durham, North Carolina. 
As with other tools developed to date, the index needs to 
be validated in other populations and settings before being 
used universally.
Strategic approaches to curtailing 
PIM prescribing
Conceptually, PIM prescribing in the inpatient setting is a 
multi-faceted function of the patient, prescriber, and envi-
ronment. First, the clinical needs of the patient must be the 
primary determinant of prescribing decisions. Appropriate 
prescribing should aim to promote the use of evidence-based 
therapies while minimizing the use of medications for which 
there is no clinical need, questionable evidence, or duplica-
tion. The patient’s perceptions and preferences should also be 
considered. Second, prescribing is done mainly by providers 
who use their own clinical experience and attitudes in making 
medication decisions. Factors that contribute to PIM prescrib-
ing include inadequate training in geriatric pharmacotherapy 
as well as the absence of communication between providers 
practicing in different settings, or between specialists and the 
primary care provider. Finally, the environment in which the 
prescriber operates can affect prescribing decisions. Unfor-
tunately, the acute care setting does not encourage review of 
chronic and preventive medications. Furthermore, the inpa-
tient environment may lack the technological infrastructure 
to share information relating to drugs during transitions of 
care, which ultimately compromises quality.
With this in mind, several strategic approaches exist to 
potentially minimize PIM prescribing. The question sur-
rounding which tool to use to measure quality of prescribing 
remains controversial. Quality measures are often chosen not 
only because of the clinical importance of the construct they 
measure but also their ease of use. In particular, drugs-to-
avoid criteria have been a popular tool for research, in part 
due to their easy applicability to administrative databases. 
Although easy-to-administer measures such as drugs-to-
avoid criteria (eg, Beers’ criteria) capture useful elements 
of prescribing quality, that the relative ease of these metrics Clinical Interventions in Aging 2010:5 85
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creates an immediate danger that they will drive quality 
assessment and improvements efforts rather than vice versa. 
In fact, significant discordance exists between the MAI 
and Beers’ criteria when using these tools to evaluate drug 
prescribing quality in similar populations.47 Furthermore, 
when prescribing, one must take into account the patient as a 
whole, including his or her life expectancy and quality of life 
within a social and economical environment, select essential 
medications, and avoid drugs with a poorer benefit-to-risk 
ratio. Unfortunately, explicit prescribing criteria may force 
the prescriber to ignore these considerations by prescrib-
ing at the bedside according to inflexible, rigid guidelines. 
  Therefore, based on these observations, because using a 
single tool may fail to capture the overall quality of a patient’s 
  medication regimen, it would seem prudent to consider 
employing multiple tools and multifaceted perspectives to 
capture the range of quality problems that may be present in 
medication prescribing.
While primarily documented in the ambulatory setting, 
additional strategies for hospital settings consist of using a 
computerized decision support system, implementing didactic 
educational programs within the health system, utilizing clini-
cal pharmacist expertise on clinical rounds or for prospective 
medication review, and considering a comprehensive geriatric 
evaluation and management (GEM) care approach.5,48–56 This 
latter approach consists of a multidisciplinary team, which 
may include a geriatrician and other health care providers 
with specialized geriatric training (eg, nurses, pharmacists, 
dieticians, social workers, and psychologists). Data from the 
inpatient setting suggest that employing a GEM care team 
can lower potential drug-drug interactions and the number of 
unnecessarily prescribed drugs from admission to discharge, 
as well as decrease the time to discharge.5,52–54 Finally, infra-
structure and hospital policies to provide medication recon-
ciliation on admission and at discharge are crucial in response 
to medication discrepancies within the inpatient setting 
documented as problematic. Coleman and colleagues found 
that 14% of older community-dwelling patients experienced 
post-hospital medication discrepancies within two weeks of 
discharge, and that half of those discrepancies were system-
related.16 Presently, medication reconciliation is included in 
the Joint Commission’s National Patient Safety Goals. Goal 
8 states that hospitals must “accurately and completely rec-
oncile patient medications across the continuum of care.”57 
In order to prevent fragmentation of care from the inpatient 
to the outpatient setting, clinical pharmacists and nurses 
have served as potential medication transition coordinators 
and discharge advocates. Data from two studies suggest that 
such an approach can lower the rate of hospital readmission 
and emergency department visits.50,58
Summary and future concerns
The prescribing of medications is a fundamental compo-
nent of the care of the elderly, and the optimization of drug 
prescribing has become an important public health concern. 
The inpatient setting can be particularly hazardous regarding 
ADEs due to the problem of multiple prescribers, medica-
tion reconciliation issues, and poor communication between 
outpatient and inpatient providers. While tools are available 
to identify PIM prescribing and potential strategies exist to 
curtail the problem, several fundamental issues still exist. 
First, from an interventional and health care research per-
spective, even though data provide useful insights into the 
effectiveness of different approaches, the effect on impor-
tant health outcomes and health care costs still needs to be 
evaluated. Second, despite substantial resource dedication 
to developing and testing the effectiveness of interventions 
to improve prescribing, widespread diffusion of success-
ful methods has not yet been achieved. It also seems that 
our current culture, from the perspective of patients and 
prescribers, relies too heavily on pharmacological interven-
tions to address medical problems. The use of medications 
is often the first and only intervention sought, when other 
proven interventions, such as psychotherapy for behavioral 
and mental health issues, may be appropriate. Also, to fully 
address appropriateness of prescribing, not only should the 
use of inappropriate medications be avoided, but the use of 
indicated and beneficial medications should be encouraged. 
In this instance, evidence-based criteria, such as the START 
(Screening Tool to Alert doctors to Right Treatment) criteria 
should compliment assessments.59 Finally, the responsibility 
of appropriate prescribing should no longer fall solely on the 
shoulders of physician prescriber. Rather the responsibility 
should be shared across the multidisciplinary continuum of 
care with all health care professionals who provide care for 
the older adult.
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